Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $205.48, for a total transaction of $410,960.00. Following the completion of the transaction, the executive vice president now owns 30,370 shares of the company’s stock, valued at $6,240,427.60. The sale was disclosed in a document filed with the SEC, which is available through this link.

Marc Stapley also recently made the following trade(s):

  • On Thursday, October 26th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $206.88, for a total transaction of $413,760.00.
  • On Tuesday, September 5th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $205.93, for a total transaction of $411,860.00.

Illumina, Inc. (ILMN) opened at $209.02 on Friday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The stock has a market cap of $30,520.00, a P/E ratio of 60.25, a P/E/G ratio of 3.40 and a beta of 0.74. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $214.50.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm’s revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.97 earnings per share. analysts expect that Illumina, Inc. will post 3.75 EPS for the current year.

WARNING: “Marc Stapley Sells 2,000 Shares of Illumina, Inc. (ILMN) Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/18/marc-stapley-sells-2000-shares-of-illumina-inc-ilmn-stock.html.

ILMN has been the subject of several research reports. BidaskClub lowered shares of Illumina from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 25th. Canaccord Genuity reiterated a “hold” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, July 26th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target for the company in a research note on Thursday, July 27th. Deutsche Bank AG set a $175.00 price target on shares of Illumina and gave the stock a “hold” rating in a research note on Friday, July 28th. Finally, First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target for the company in a research note on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the stock. Illumina currently has a consensus rating of “Hold” and a consensus target price of $200.88.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Paradigm Asset Management Co. LLC boosted its holdings in shares of Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Illumina by 1.4% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after buying an additional 43 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Illumina by 298.7% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock worth $1,813,000 after buying an additional 7,827 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in shares of Illumina in the second quarter worth approximately $27,175,000. Finally, Intellectus Partners LLC boosted its holdings in shares of Illumina by 6.6% in the second quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock worth $1,871,000 after buying an additional 664 shares during the last quarter. 92.70% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.